Search Results for "A-200"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for A-200. Results 301 to 310 of 660 total matches.
Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
7.3016
Oral Progestogens
Progesterone (micronized) – generic 100, 200 mg caps 100 mg PO once/day17 ...
The FDA has approved Bijuva (TherapeuticsMD), a
fixed-dose combination of estradiol and progesterone,
for oral treatment of moderate to severe vasomotor
symptoms (hot flashes) due to menopause in women
with an intact uterus. The manufacturer is marketing
Bijuva as "the first and only FDA-approved combination
of bio-identical estradiol and bio-identical progesterone
in a single daily oral capsule".
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
tabs 50 or 100 mg PO; can be repeated 1.40/73.509
Imitrex (GSK) after 2 hrs (max 200 mg/day)
6 mg/0.5 ...
An oral nonopioid analgesic is often sufficient for
acute treatment of mild to moderate migraine pain
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine in most patients without vascular disease.
Treatment of pain when it is still mild to moderate in
intensity improves headache response and reduces
the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96 doi:10.58347/tml.2023.1678a | Show Introduction Hide Introduction
Pioglitazone (Actos)
The Medical Letter on Drugs and Therapeutics • Nov 19, 1999 (Issue 1066)
dosage Cost
1
Troglitazone − Rezulin (Parke-Davis) 200 to 600 mg once
2
89.28
Rosiglitazone ...
Pioglitazone is the third thiazolidinedione ("glitazone") to be marketed in the USA for treatment of type 2 diabetes. Thiazolidinediones decrease resistance to insulin.
Treatment of COVID-19 in High-Risk Outpatients (online only)
The Medical Letter on Drugs and Therapeutics • Jan 28, 2022 (Issue 1643)
(Veklury)
• Dosage: 200 mg IV day 1, then 100 mg IV days 2 and 35
• Begin ≤7 days after symptom onset ...
View the Treatment of COVID-19 in High-Risk Outpatients Chart
Comparison Chart: Interleukin (IL) Receptor Antagonists for Atopic Dermatitis (online only)
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025 (Issue 1722)
– Dupixent (Sanofi/Regeneron) 200 mg/1.14 mL, 300 mg/2 mL prefilled pens, syringes IL-4 and IL-13 inhibitor ...
View the Comparison Chart: Interleukin (IL) Receptor Antagonists for Atopic Dermatitis
Med Lett Drugs Ther. 2025 Feb 17;67(1722):e1 doi:10.58347/tml.2025.1722f | Show Introduction Hide Introduction
A New Ace Inhibitor and Two New Angiotensin Receptor Blockers For Hypertension
The Medical Letter on Drugs and Therapeutics • Nov 05, 1999 (Issue 1065)
in about 200 patients with mild-to-moderate hypertension not well controlled by hydrochlorothiazide ...
Perindopril, the tenth angiotensin converting enzyme (ACE) inhibitor to be marketed in the USA, and telmisartan and eprosartan, the fifth and sixth angiotensin receptor blockers, have recently become available for treatment of hypertension.
Beta-blockers For Heart Failure
The Medical Letter on Drugs and Therapeutics • Jun 26, 2000 (Issue 1081)
2
− Toprol XL (AstraZeneca) 12.5 to 25 mg once/day 200 mg once/day 49.13
1. Cost to the patient ...
Standard treatment for patients with heart failure has included a diuretic, digitalis and an ACE inhibitor. In recent years carvedilol, a nonselective beta-blocker with alpha-1 blocking activity, and the beta-selective blockers bisoprolol and metroprolol have also been used for this indication.
Darbepoetin (Aranesp) - A long-acting Erythropoietin
The Medical Letter on Drugs and Therapeutics • Dec 10, 2001 (Issue 1120)
.
DOSAGE AND COST — Darbepoetin is available in single-dose vials of 25, 40, 60, 100
and 200 mcg ...
Darbepoetin alfa (Aranesp) has been approved by the FDA for treatment of anemia caused by chronic renal disease and will probably also be approved for use in patients with cancer..
Valdecoxib (Bextra) - a New Cyclooxygenase-2 Inhibitor
The Medical Letter on Drugs and Therapeutics • Apr 29, 2002 (Issue 1129)
(Celebrex − Pharmacia/Pfizer) 200 mg once/day to 100-200 mg bid $ 75.00
Rofecoxib (Vioxx − Merck) 12.5-25 ...
Valdecoxib (Bextra - Pharmacia/Pfizer), a selective cyclooxygenase (COX-2) inhibitor similar to celecoxib (Celebrex) and rofecoxib (Vioxx), was recently approved by the FDA for treatment of osteoarthritis, rheumatoid arthritis and primary dysmenorrhea.
Oxaliplatin (Eloxatin) for Advanced Colon Cancer
The Medical Letter on Drugs and Therapeutics • Jan 20, 2003 (Issue 1148)
, which included 200 patients, reported progression-free survival of 8.7 months with the
oxaliplatin ...
Oxaliplatin (Eloxatin -Sanofi-Synthelabo) has been approved by the FDA for use in combination with fluorouracil (5-FU; Adrucil, and others) and leucovorin (LV; Wellcovorin) for patients with metastatic colorectal cancer whose disease has recurred or progressed despite treatment with 5-FU/LV plus irinotecan (Camptosar - Medical Letter 1997; 39:8).